Bispecific antibodies against human PD-L1 and human OX40 and their applications

By designing a bispecific antibody that can simultaneously bind to PD-L1 and OX40 to activate T cells, the problem of insufficient efficacy of PD-L1 and OX40 bispecific antibodies in existing technologies has been solved, achieving highly efficient treatment of tumors.

CN117402255BActive Publication Date: 2026-11-17NANJING UMAB-RUICARE BIOTECH CO LTD +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202210827257.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-07-13
Publication Date
2026-11-17
Estimated Expiration
2042-07-13

AI Technical Summary

Technical Problem

Existing PD-L1 and OX40 bispecific antibodies are insufficient in tumor treatment, failing to effectively synergistically activate T cells and thus failing to fully realize the potential of tumor treatment.

Method used

A bispecific antibody was designed that can simultaneously bind to PD-L1 and OX40 proteins. By specifically binding to PD-L1 on the surface of tumor cells and OX40 on the surface of T cells, it activates T cells and enhances the immune system's ability to attack tumors.

Benefits of technology

It achieves highly efficient activation of T cells, enhancing the therapeutic effect on tumors, especially showing significant tumor therapeutic effects on tumor cells that highly express PD-L1.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003744466260000021
    Figure BDA0003744466260000021
  • Figure BDA0003744466260000031
    Figure BDA0003744466260000031
  • Figure BDA0003744466260000041
    Figure BDA0003744466260000041
Patent Text Reader

Abstract

This invention provides a bispecific antibody against human PD-L1 and human OX40 and its applications. The bispecific antibody of this invention can simultaneously target PD-L1 on the surface of tumor cells and OX40 on the surface of T cells. The bispecific antibody of this invention exhibits high activity in targeting and blocking the interaction between PD-L1 and PD1, and only generates moderate OX40 agonistic activity after binding to PD-L1 on the tumor surface; therefore, its OX40 agonistic activity is tumor microenvironment specific.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the pharmaceutical field. Specifically, it relates to a bispecific antibody against human PD-L1 and human OX40 and its applications. Background Technology

[0002] Programmed death-ligand 1 (PD-L1), also known as CD274 or B7-H1, is a 40 kDa type I transmembrane protein that plays a major role in suppressing the immune system. The binding of PD-L1 to PD-1 generates an inhibitory signal, suppressing the proliferation of antigen-specific T cells while reducing apoptosis of regulatory T cells (Treg cells). Therefore, tumor cells that highly express PD-L1 can evade immune surveillance through this immunosuppressive effect. Many PD-L1 inhibitors are under development as immuno-oncology therapies; marketed PD-L1 antibodies include Durvalumab, Atezolizumab, and Avelumab.

[0003] OX40 is an immune co-stimulatory molecule. Human OX40 is primarily expressed on activated T cells, including CD4, CD8, Th, and Treg cells. OX40 expression on T cells is low, but its expression level is upregulated after antigen-induced stimulation, reaching a peak within 12 hours to 5-6 days. Activation of antigen-dependent OX40L / OX40 co-stimulatory molecules is coupled with multiple signaling pathways within T cells, including the NF-κB, PKB / PI3K, and NFAT signaling pathways, thereby regulating T cell proliferation, apoptosis, and cytokine secretion activity, ultimately enhancing the vitality of the immune system. Based on these findings, OX40 has become an important target for immunotherapy, and numerous preclinical and clinical studies suggest that OX40 can serve as a significant target for tumor immunotherapy. Currently, most OX40 agonists in clinical trials are monoclonal antibodies, characterized by the need for the drug to bind to FcR expressed on APC cells and form multimers before exerting its T cell activation effect.

[0004] Since drugs targeting the PD-L1 / PD1 pathway can relieve the inhibition of T cells by tumor cells that highly express PD-L1, promote the activation of the TCR signaling pathway, and thus induce the upregulation of OX40 expression on T cells, creating conditions for OX40-targeting immune agonists to exert their effects, the combined use of PD-L1 / PD1 inhibitors and OX40 agonists, or bispecific antibodies that simultaneously target the two signaling pathways, is expected to have a synergistic effect on T cell activation and achieve better tumor treatment results.

[0005] Since current bispecific antibodies against PD-L1 and human OX40 still have many shortcomings, there is still a need in the art to provide a novel bispecific antibody against human PD-L1 and human OX40. Summary of the Invention

[0006] The purpose of this invention is to provide a bispecific antibody against human PD-L1 and human OX40 and its application.

[0007] In a first aspect of the present invention, a bispecific antibody is provided, the bispecific antibody comprising:

[0008] First antigen-binding domain D1; and

[0009] Second antigen-binding domain D2;

[0010] Specifically, the first antigen-binding domain D1 specifically binds to the PD-L1 protein;

[0011] The second antigen-binding domain D2 specifically binds to the OX40 protein.

[0012] In another preferred embodiment, D1 is an anti-PD-L1 antibody or its antigen-binding fragment.

[0013] In another preferred embodiment, D2 is an anti-OX40 antibody or its antigen-binding fragment.

[0014] In another preferred embodiment, the antigen-binding fragment is selected from the group consisting of: (i) Fab fragment; (ii) F(ab')2 fragment; (iii) Fd fragment; (iv) Fv fragment; (v) single-chain Fv (scFv) molecule; or (vi) dAb fragment.

[0015] In another preferred embodiment, the antibody is selected from the group consisting of nanobodies, single-chain antibodies, and double-chain antibodies.

[0016] In another preferred embodiment, the antibody is selected from the group consisting of: animal-derived antibodies (such as mouse-derived antibodies), chimeric antibodies, and humanized antibodies.

[0017] In another preferred embodiment, the anti-PD-L1 antibody is an anti-human PD-L1 antibody.

[0018] In another preferred embodiment, the anti-OX40 antibody is an anti-human OX40 antibody.

[0019] In another preferred embodiment, the antibody or its antigen-binding fragment is in monovalent or multivalent form (e.g., bivalent form).

[0020] In another preferred embodiment, D1 and D2 are connected directly or via a connector.

[0021] In another preferred embodiment, D2 is an anti-OX40 antibody, and D1 is linked to a region of the anti-OX40 antibody selected from the group consisting of: a heavy chain variable region, a heavy chain constant region, a light chain variable region, a light chain constant region, or a combination thereof.

[0022] In another preferred embodiment, the D1 is attached to the start of the heavy chain variable region of the anti-OX40 antibody.

[0023] In another preferred embodiment, the D1 is attached to the end of the heavy chain constant region of the anti-OX40 antibody.

[0024] In another preferred embodiment, the D1 is attached to the start of the light chain variable region of the anti-OX40 antibody.

[0025] In another preferred embodiment, the D1 is attached to the end of the light chain constant region of the anti-OX40 antibody.

[0026] In another preferred embodiment, D1 is an anti-PD-L1 antibody, and D2 is linked to a region of the anti-PD-L1 antibody selected from the group consisting of: a heavy chain variable region, a heavy chain constant region, a light chain variable region, a light chain constant region, or a combination thereof.

[0027] In another preferred embodiment, the D2 is attached to the start of the heavy chain variable region of the anti-PD-L1 antibody.

[0028] In another preferred embodiment, the D2 is attached to the end of the heavy chain constant region of the anti-PD-L1 antibody.

[0029] In another preferred embodiment, the D2 is attached to the start of the light chain variable region of the anti-PD-L1 antibody.

[0030] In another preferred embodiment, the D2 is attached to the end of the light chain constant region of the anti-PD-L1 antibody.

[0031] In another preferred embodiment, the bispecific antibody is a homodimer.

[0032] In another preferred embodiment, the bispecific antibody has the structure shown in Formula I from the N-terminus to the C-terminus:

[0033]

[0034] in,

[0035] Each D1 is independently an anti-PD-L1 antibody or its antigen-binding fragment, and at least one D1 is an anti-PD-L1 antibody or its antigen-binding fragment;

[0036] L1, L2, L3, and L4 are each independently keyless, keyless, or connectors;

[0037] VLa represents the light chain variable region of the anti-OX40 antibody;

[0038] CLa represents the light chain constant region of the anti-OX40 antibody;

[0039] VHa represents the heavy chain variable region of the anti-OX40 antibody;

[0040] CHa represents the heavy chain constant region of the anti-OX40 antibody;

[0041] "~" represents a disulfide bond or a covalent bond;

[0042] "-" represents a peptide bond;

[0043] The bispecific antibody has the activity of simultaneously binding to PD-L1 and OX40.

[0044] In another preferred embodiment, the bispecific antibody has the structure shown in Formula II from the N-terminus to the C-terminus:

[0045]

[0046] in,

[0047] Each D2 is independently either an anti-OX40 antibody or an antigen-binding fragment thereof, and at least one D2 is an anti-OX40 antibody or an antigen-binding fragment thereof;

[0048] L1, L2, L3, and L4 are each independently keyless, keyless, or connectors;

[0049] VLb represents the light chain variable region of the anti-PD-L1 antibody;

[0050] CLb represents the light chain constant region of the anti-PD-L1 antibody;

[0051] VHb represents the heavy chain variable region of the anti-PD-L1 antibody;

[0052] CHb represents the heavy chain constant region of the anti-PD-L1 antibody;

[0053] "~" represents a disulfide bond or a covalent bond;

[0054] "-" represents a peptide bond;

[0055] The bispecific antibody has the activity of simultaneously binding to PD-L1 and OX40.

[0056] In another preferred embodiment, L1, L2, L3, and L4 may be the same or different.

[0057] In another preferred embodiment, L1, L2, L3, and L4 are each independently selected from the following group:

[0058] None or Gn (n selected from 1-10), (GS)n, (G4S)n (n selected from 1-4), G4SG, GGSGG, SSSSKAPPPSLPSPSRLPGPSDTPILPQ (SEQ ID NO.32), (G)nSSSSKAPPPSLPSPSRLPGPSDTPILPQ(G)m (n selected from 1-5, m selected from 1-5).

[0059] In another preferred embodiment, the bispecific antibody is formed by fusing an antigen-binding fragment of an anti-OX40 antibody and an anti-PD-L1 antibody, and has two symmetrical pairs of peptide chains, each pair containing a light chain (L chain) and a heavy chain (H chain), all of which are linked by disulfide bonds. Any pair of peptide chains has the L chain and H chain structure shown in formula Ia, Ib, or Ic from the N-terminus to the C-terminus.

[0060]

[0061] in,

[0062] D1 is the antigen-binding fragment of the anti-PD-L1 antibody;

[0063] L1 is either empty or connected;

[0064] VLa represents the light chain variable region of the anti-OX40 antibody;

[0065] CLa represents the light chain constant region of the anti-OX40 antibody;

[0066] VHa represents the heavy chain variable region of the anti-OX40 antibody;

[0067] CHa represents the heavy chain constant region of the anti-OX40 antibody;

[0068] "~" represents a disulfide bond or a covalent bond;

[0069] "-" represents a peptide bond;

[0070] The bispecific antibody has the activity of simultaneously binding to PD-L1 and OX40.

[0071] In another preferred embodiment, the bispecific antibody is formed by fusing an antigen-binding fragment of an anti-PD-L1 antibody and an anti-OX40 antibody, and has two symmetrical pairs of peptide chains, each pair containing a light chain (L chain) and a heavy chain (H chain), all of which are linked by disulfide bonds, wherein any pair of peptide chains has the L chain and H chain structure shown in formula IIa, IIb, or IIc from the N-terminus to the C-terminus.

[0072]

[0073] in,

[0074] D2 is the antigen-binding fragment of the anti-OX40 antibody;

[0075] L1 is either empty or connected;

[0076] VLb represents the light chain variable region of the anti-PD-L1 antibody;

[0077] CLb represents the light chain constant region of the anti-PD-L1 antibody;

[0078] VHb represents the heavy chain variable region of the anti-PD-L1 antibody;

[0079] CHb represents the heavy chain constant region of the anti-PD-L1 antibody;

[0080] "~" represents a disulfide bond or a covalent bond;

[0081] "-" represents a peptide bond;

[0082] The bispecific antibody has the activity of simultaneously binding to PD-L1 and OX40.

[0083] In another preferred embodiment, the anti-PD-L1 antibody or its antigen-binding fragment is an anti-PD-L1 scFv, Fv fragment or VHH.

[0084] In another preferred embodiment, the anti-OX40 antibody or its antigen-binding fragment is an anti-OX40 scFv, Fv fragment or VHH.

[0085] In another preferred embodiment, the heavy chain variable region (VH) of the anti-PD-L1 antibody or its antigen-binding fragment is as shown in SEQ ID NO.1; and the light chain variable region (VL) of the anti-PD-L1 antibody or its antigen-binding fragment is as shown in SEQ ID NO.2.

[0086] In another preferred embodiment, the heavy chain variable region (VH) of the anti-OX40 antibody or its antigen-binding fragment is as shown in SEQ ID NO.3; and the light chain variable region (VL) of the anti-OX40 antibody or its antigen-binding fragment is as shown in SEQ ID NO.4.

[0087] In another preferred embodiment, the bispecific antibody has a heavy chain (H chain) and a light chain (L chain).

[0088] In another preferred embodiment, the bispecific antibody has an amino acid sequence selected from the group consisting of:

[0089] (1) The H chain as shown in SEQ ID NO.5; and the L chain as shown in SEQ ID NO.6;

[0090] (2) The H chain as shown in SEQ ID NO.5; and the L chain as shown in SEQ ID NO.7;

[0091] (3) The H chain as shown in SEQ ID NO.8; and the L chain as shown in SEQ ID NO.9;

[0092] (4) The H chain as shown in SEQ ID NO. 10; and the L chain as shown in SEQ ID NO. 9;

[0093] (5) The H chain as shown in SEQ ID NO. 11; and the L chain as shown in SEQ ID NO. 9;

[0094] (6) The H chain as shown in SEQ ID NO. 12; and the L chain as shown in SEQ ID NO. 13;

[0095] (7) The H chain as shown in SEQ ID NO.18; and the L chain as shown in SEQ ID NO.19;

[0096] (8) The H chain as shown in SEQ ID NO.22; and the L chain as shown in SEQ ID NO.19;

[0097] (9) The H chain as shown in SEQ ID NO.23; and the L chain as shown in SEQ ID NO.19;

[0098] (10) The H chain as shown in SEQ ID NO.30; and the L chain as shown in SEQ ID NO.31;

[0099] (11) The H chain as shown in SEQ ID NO.14; and the L chain as shown in SEQ ID NO.15;

[0100] (12) The H chain as shown in SEQ ID NO.16; and the L chain as shown in SEQ ID NO.17;

[0101] (13) The H chain as shown in SEQ ID NO.20; and the L chain as shown in SEQ ID NO.17;

[0102] (14) The H chain as shown in SEQ ID NO.21; and the L chain as shown in SEQ ID NO.17;

[0103] (15) The H chain as shown in SEQ ID NO.24; and the L chain as shown in SEQ ID NO.17;

[0104] (16) The H chain as shown in SEQ ID NO.25; and the L chain as shown in SEQ ID NO.26;

[0105] (17) The H chain as shown in SEQ ID NO.27; and the L chain as shown in SEQ ID NO.26;

[0106] (18) The H chain as shown in SEQ ID NO. 28; and the L chain as shown in SEQ ID NO. 26; or

[0107] (19) The H chain as shown in SEQ ID NO.29; and the L chain as shown in SEQ ID NO.26.

[0108] In another preferred embodiment, the bispecific antibody further includes an active fragment and / or derivative of the bispecific antibody, wherein the active fragment and / or the derivative retains 70-100% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100%) of the anti-PD-L1 activity and 70-100% of the anti-OX40 activity of the bispecific antibody.

[0109] In another preferred embodiment, the antibody derivative has at least 85% sequence identity with the antibody of the present invention.

[0110] In another preferred embodiment, the antibody derivative is a sequence of the antibody of the present invention that has undergone one or more amino acid deletions, insertions and / or substitutions and retains at least 85% identity.

[0111] In another preferred embodiment, the antibody derivative has at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% sequence identity with the antibody of the present invention.

[0112] In a second aspect of the invention, an isolated polynucleotide is provided, said polynucleotide encoding the bispecific antibody described in the first aspect of the invention.

[0113] In another preferred embodiment, the polynucleotide has a polynucleotide encoding the L chain of the bispecific antibody.

[0114] In another preferred embodiment, the polynucleotide has a polynucleotide encoding the H chain of the bispecific antibody.

[0115] In a third aspect of the invention, a carrier is provided, the carrier containing the polynucleotide described in the second aspect of the invention.

[0116] In another preferred embodiment, the carrier simultaneously contains all the polynucleotides described in the second aspect of the invention.

[0117] In another preferred embodiment, the carrier contains the polynucleotides described in the second aspect of the present invention.

[0118] In another preferred embodiment, the carrier is an expression carrier.

[0119] In another preferred embodiment, the vector includes plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses, or other vectors.

[0120] In a fourth aspect of the invention, a genetically engineered host cell is provided, the host cell containing the vector or genome described in the third aspect of the invention, or the polynucleotides described in the second aspect of the invention integrated into the genome.

[0121] In a fifth aspect of the invention, a method for preparing the antibody described in the first aspect of the invention is provided, comprising the steps of:

[0122] (i) Under suitable conditions, the host cells described in the fourth aspect of the present invention are cultured to obtain a mixture containing the bispecific antibody described in the first aspect of the present invention; and

[0123] (ii) The mixture obtained in step (i) is purified and / or separated to obtain the bispecific antibody described in the first aspect of the invention.

[0124] In another preferred embodiment, the purification can be carried out by a protein A affinity column, or by further combining ion exchange chromatography, molecular sieving, or other methods to purify and separate the target antibody.

[0125] In another preferred embodiment, the purity of the purified and separated target antibody is greater than 80%, greater than 90%, greater than 95%, greater than 96%, greater than 97%, and preferably greater than 98%.

[0126] In a sixth aspect of the invention, a pharmaceutical composition is provided, the pharmaceutical composition comprising:

[0127] (I) the bispecific antibody as described in the first aspect of the invention; and

[0128] (II) Pharmaceutically acceptable carriers.

[0129] In another preferred embodiment, the pharmaceutical composition further contains an additional antitumor agent.

[0130] In another preferred embodiment, the pharmaceutical composition is a unit dosage form.

[0131] In another preferred embodiment, the antitumor agent comprises paclitaxel, doxorubicin, cyclophosphamide, axitinib, lenvatinib, or pembrolizumab.

[0132] In another preferred embodiment, the antitumor agent may be present separately from the bispecific antibody in a separate package, or the antitumor agent may be conjugated to the bispecific antibody.

[0133] In another preferred embodiment, the parenteral dosage form includes intravenous injection, intravenous drip, subcutaneous injection, local injection, intramuscular injection, intratumoral injection, intraperitoneal injection, intracranial injection, or intracavitary injection.

[0134] In a seventh aspect of the invention, an immunoconjugate is provided, the immunoconjugate comprising:

[0135] (a) the bispecific antibody as described in the first aspect of the invention; and

[0136] (b) The coupling part selected from the group consisting of: detectable markers, drugs, toxins, cytokines, radionuclides, enzymes, or combinations thereof.

[0137] In another preferred embodiment, the conjugate is partially selected from: fluorescent or luminescent markers, radiolabels, MRI (magnetic resonance imaging) or CT (computed tomography) contrast agents, or enzymes, radionuclides, biotoxins, cytokines (such as IL-2), antibodies, antibody Fc fragments, antibody scFv fragments, gold nanoparticles / nanorobars, viral particles, liposomes, magnetic nanoparticles, prodrug-activating enzymes (e.g., DT-cardiacinase (DTD) or biphenyl hydrolase-like protein (BPHL)), chemotherapeutic agents (e.g., cisplatin), or any form of nanoparticles.

[0138] In another preferred embodiment, the antibody portion is coupled to the coupling portion via a chemical bond or a linker.

[0139] In an eighth aspect of the invention, the use of a bispecific antibody as described in the first aspect of the invention or an immunoconjugate as described in the seventh aspect of the invention is provided for the preparation of (a) a detection reagent or kit; and / or (b) a pharmaceutical composition for the prevention and / or treatment of cancer or tumors.

[0140] In another preferred embodiment, the tumor is selected from the group consisting of hematologic malignancies, solid tumors, or combinations thereof.

[0141] In another preferred embodiment, the tumor is selected from the group consisting of: ovarian cancer, colon cancer, rectal cancer, melanoma, kidney cancer, bladder cancer, breast cancer, liver cancer, lymphoma, hematologic malignancies, head and neck cancer, glioma, gastric cancer, nasopharyngeal carcinoma, laryngeal cancer, cervical cancer, endometrial tumor, osteosarcoma, or combinations thereof.

[0142] In another preferred embodiment, the tumor is rectal cancer, non-small cell lung cancer, melanoma, bladder cancer, or a combination thereof.

[0143] In another preferred embodiment, the tumor is a tumor that highly expresses PD-L1.

[0144] In another preferred embodiment, the drug or formulation is used to prepare a drug or formulation for the prevention and / or treatment of diseases associated with PD-L1 and / or OX40 (positive expression).

[0145] In another preferred embodiment, the antibody is in the form of a drug conjugate (ADC).

[0146] In another preferred embodiment, the test reagent or kit is used to diagnose PD-L1 and / or OX40-related diseases.

[0147] In another preferred embodiment, the detection reagent or kit is used to detect PD-L1 and / or OX40 proteins in a sample.

[0148] In another preferred embodiment, the detection reagent is a detection strip.

[0149] In a ninth aspect of the invention, a method for treating a tumor is provided, comprising the steps of: administering to a desired subject a safe and effective amount of the bispecific antibody of the first aspect of the invention, or the pharmaceutical composition of the sixth aspect of the invention, or the immunoconjugate of the seventh aspect of the invention, or a combination thereof.

[0150] It should be understood that, within the scope of this invention, the above-described technical features of this invention and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. Attached Figure Description

[0151] Figure 1 A schematic diagram of the dual-antibody structure of the present invention is shown.

[0152] Figure 2 The results show the affinity of the bispecific antibodies of the present invention to human PD-L1 and human OX40.

[0153] Figure 3 The bispecific antibody of the present invention was demonstrated to inhibit tumors in a mouse tumor pharmacological model.

[0154] Figure 4 The binding of L26 to the target protein was demonstrated by an ELISA.

[0155] Figure 5 The PK curves of L26 cynomolgus monkeys are shown.

[0156] Figure 6 The study demonstrated the proliferative activity of L26 on CD4 / CD8 cells in a cynomolgus monkey model.

[0157] Figure 7 The thermal melting curve of L26 is shown.

[0158] Figure 8 The thermal stability of L26 samples was demonstrated by an ELISA assay showing the binding of human PD-L1 and human OX40 proteins. Detailed Implementation

[0159] Through extensive and in-depth research, the inventors have unexpectedly discovered for the first time a bispecific antibody that can simultaneously target PD-L1 on the surface of tumor cells and OX40 protein on the surface of T cells. This antibody is based on the inventors' previously discovered OX40 activating antibody (Chinese Patent 201711476160.3) and PD-L1 inhibitory antibody (Chinese Patent 2018114326870). The bispecific antibody of this invention exhibits high activity in targeting and blocking PD-L1-PD1 interaction, and only generates moderate OX40 agonistic activity after binding to PD-L1 on the tumor surface. Therefore, its OX40 agonistic activity has a certain tumor microenvironment specificity. This invention was completed based on this discovery.

[0160] the term

[0161] To facilitate understanding of the invention, certain technical and scientific terms are specifically defined below. Unless otherwise expressly defined herein, all other technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art to which this invention pertains.

[0162] The amino acid three-letter codes and single-letter codes used in this invention are as described in J. biol. chem, 243, p3558 (1968).

[0163] As used herein, the terms “administer” and “treatment” refer to the application of an exogenous drug, therapeutic agent, diagnostic agent, or composition to an animal, human, subject, cell, tissue, organ, or biological fluid. “Administer” and “treatment” can refer to therapeutic, pharmacokinetic, diagnostic, research, and experimental methods. Cellular treatment includes contact between a reagent and a cell, as well as contact between a reagent and a fluid, and contact between a fluid and a cell. “Administer” and “treatment” also mean treatment by means of a reagent, diagnostic agent, conjugate composition, or another cell in vitro and ex vivo. When applied to a human, animal, or research subject, “treatment” refers to therapeutic treatment, prophylactic or preventative measures, research, and diagnostic procedures; including contact between bispecific antibodies and a human or animal, subject, cell, tissue, physiological compartment, or physiological fluid.

[0164] As used herein, the term "treatment" refers to the administration of an oral or topical therapeutic agent, comprising any of the bispecific antibodies and compositions thereof of the present invention, to a patient having one or more disease symptoms, for which the therapeutic agent is known to have a therapeutic effect. Typically, the therapeutic agent is administered to the patient in an amount that effectively relieves the symptoms of one or more diseases (therapeutic effective amount).

[0165] As used herein, the terms “optional” or “optionally” mean that the events or conditions described below may occur but are not required to occur. For example, “optionally containing 1-3 antibody heavy chain variable regions” means that the antibody heavy chain variable regions of a particular sequence may be present but are not required to be present, and may be 1, 2 or 3.

[0166] The term "sequence identity" as used in this invention refers to the degree of identity between two nucleic acid or two amino acid sequences when optimally aligned and compared with appropriate mutations such as substitutions, insertions, or deletions. The sequence identity between the sequences described in this invention and sequences exhibiting identity with them can be at least 85%, 90%, or 95%, preferably at least 95%. Non-limiting embodiments include 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and 100%.

[0167] Antibodies, also known as immunoglobulins, can be natural or conventional. They consist of two heavy chains linked together by disulfide bonds, and each heavy chain is connected to a light chain by a disulfide bond. There are two types of light chains, λ(l) and κ(k). Five main heavy chain types (or isotypes) exist, which determine the functional activity of the antibody molecule: IgM, IgD, IgG, IgA, and IgE. Each chain contains different sequence domains. Light chains include two domains or regions, a variable domain (VL) and a constant domain (CL). Heavy chains include four domains: a variable region (VH) and three constant regions (CH1, CH2, and CH3, collectively referred to as CH). The variable regions of both the light chain (VL) and heavy chain (VH) determine the binding recognition and specificity to antigens. The constant domains (CL) of the light chain and the constant regions (CH) of the heavy chain confer important biological properties such as antibody chain binding, secretion, transplacental mobility, complement fixation, and binding to Fc receptors (FcRs). The Fv fragment is the N-terminal portion of the immunoglobulin Fab fragment and consists of variable portions of one light chain and one heavy chain. Antibody specificity depends on the structural complementarity of the antibody binding site and the antigen-determining region. The antibody binding site is composed primarily of residues from highly variable regions or complementarity-determining regions (CDRs). Occasionally, residues from non-highly variable or frame regions (FRs) influence the overall domain structure and thus the binding site. The complementarity-determining region, or CDR, is the amino acid sequence that collectively defines the binding affinity and the specificity of the native Fv region of the native immunoglobulin binding site. Both the light and heavy chains of immunoglobulins have three CDRs, respectively designated CDR1-L, CDR2-L, CDR3-L and CDR1-H, CDR2-H, CDR3-H. A typical antibody-antigen binding site therefore comprises six CDRs, containing a set of CDRs from each heavy and light chain v region.

[0168] The complementation-determining region (CDR) is a key sequence structure that determines the specific binding of an antibody to an antigen. The heavy chain and light chain each contain three CDRs, named HCDR1, HCDR2, and HCDR3, and LCDR1, LCDR2, and LCDR3, respectively. In a given antibody's light chain variable region or heavy chain variable region amino acid sequence, the precise amino acid sequence boundaries of each CDR can be determined using any of a number of known antibody CDR assignment systems or combinations thereof, including, for example: Chothia (Chothia et al. (1989) Nature 342:877-883, Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 (1997)) based on antibody three-dimensional structure and CDR loop topology; Kabat (Kabat et al., Sequences of Proteins of Immunological Interest, 4th Edition, USDapartment of Health and Human Services, National Institutes of Health (1987)) based on antibody sequence variability; AbM (University of Bath); Contact (University College London); and the International Immuno GeneTics. The database (IMGT) and the Chothia definition based on the location of the loop structure.

[0169] Unless otherwise stated, in this invention, when referring to the position of a residue in the antibody variable region (including heavy chain variable region residues and light chain variable region residues), it means the position numbered according to the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).

[0170] Preferably, the antibody described herein is one or more of the following: full-length antibody protein, antigen-antibody binding domain protein fragment, bispecific antibody, multispecific antibody, single-chain antibody fragment (scFv), single-domain antibody (sdAb), and single-domain antibody, as well as monoclonal or polyclonal antibodies prepared from the above antibodies. The monoclonal antibody can be developed using various methods and techniques, including hybridoma technology, phage display technology, and single-lymphocyte gene cloning technology. The mainstream method is to prepare monoclonal antibodies from wild-type or transgenic mice using hybridoma technology.

[0171] The full-length antibody protein is a conventional full-length antibody protein in the art, comprising a heavy chain variable region, a light chain variable region, a heavy chain constant region, and a light chain constant region. The heavy chain variable region and light chain variable region of the protein, together with the human heavy chain constant region and the human light chain constant region, constitute a fully human full-length antibody protein. Preferably, the full-length antibody protein is IgG1, IgG2, IgG3, or IgG4. The human light chain constant region is selected from the light chain constant region of the human κ or λ subtype; more preferably, the human heavy chain constant region is the heavy chain constant region of human IgG1, and the human light chain constant region is the κ chain.

[0172] The antibodies in this invention can be full-length proteins (such as IgG1, IgG2a, IgG2b or IgG2c) or protein fragments containing antigen-antibody binding domains or antigen-binding fragments (such as Fab, F(ab'), sdAb, scFv fragments).

[0173] As used herein, non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues mimicking the hypervariable region of an antibody (e.g., independent complementarity-determining regions (CDRs) such as CDR3 peptides) or constrained FR3-CDR3-FR4 peptides. In another preferred embodiment, the antibody of the present invention or its antigen-binding fragment is selected from the group consisting of camel-derived single-domain antibodies, scFv, scFv dimers, BsFv, dsFv2, dsFv-dsFv', Fv fragments, Fab, Fab', F(ab')2, ds bifunctional antibodies, nanobodies, domain antibodies, or bivalent domain antibodies.

[0174] As used herein, the terms "single-domain antibody" and "nanobody" have the same meaning: to clone the variable region of an antibody heavy chain to construct a single-domain antibody consisting of only one heavy chain variable region. It is the smallest antigen-binding fragment with complete function. Typically, antibodies that are naturally missing the light chain and the heavy chain constant region 1 (CH1) are first obtained, and then the variable region of the antibody heavy chain is cloned to construct a single-domain antibody consisting of only one heavy chain variable region.

[0175] As used herein, the term "variable" refers to the fact that certain portions of the variable region of an antibody differ sequentially, contributing to the binding and specificity of various specific antibodies to their specific antigens. However, variability is not uniformly distributed throughout the entire variable region of an antibody. It is concentrated in three segments within the variable regions of the light and heavy chains, known as complementarity-determining regions (CDRs) or hypervariable regions. The more conserved portions of the variable region are called framework regions (FRs). The variable regions of the native heavy and light chains each contain four FRs, which are generally β-sheet configurations linked by three CDRs forming a linking loop, and in some cases may form a partially β-sheet structure. The CDRs in each chain are closely packed together by the FR regions and together with the CDRs of the other chain, form the antigen-binding site of the antibody (see Kabat et al., NIH Publ. No. 91-3242, Vol. I, pp. 647-669 (1991)). Constant regions do not directly participate in antibody-antigen binding, but they exhibit different effector functions, such as participating in antibody-dependent cytotoxicity.

[0176] As used herein, the term "frame region" (FR) refers to the amino acid sequence inserted between CDRs, specifically those portions of the variable regions of the light and heavy chains of immunoglobulins that are relatively conserved among different immunoglobulins within a single species. Each immunoglobulin light and heavy chain has four FRs, designated FR1-L, FR2-L, FR3-L, FR4-L and FR1-H, FR2-H, FR3-H, FR4-H, respectively. Accordingly, the light chain variable domain can be represented as (FR1-L)-(CDR1-L)-(FR2-L)-(CDR2-L)-(FR3-L)-(CDR3-L)-(FR4-L) and the heavy chain variable domain as (FR1-H)-(CDR1-H)-(FR2-H)-(CDR2-H)-(FR3-H)-(CDR3-H)-(FR4-H). Preferably, the FR of the present invention is a human antibody FR or a derivative thereof, wherein the derivative of the human antibody FR is substantially identical to the naturally occurring human antibody FR, that is, the sequence identity reaches 85%, 90%, 95%, 96%, 97%, 98% or 99%.

[0177] Knowing the amino acid sequence of the CDR, those skilled in the art can easily determine the frame regions FR1-L, FR2-L, FR3-L, FR4-L and / or FR1-H, FR2-H, FR3-H, FR4-H.

[0178] As used herein, the term "human frame region" is a frame region that is substantially identical (approximately 85% or more, specifically 90%, 95%, 97%, 99%, or 100%) to the frame region of a naturally occurring human antibody.

[0179] As used herein, the terms “monoclonal antibody” or “mAb” refer to an antibody molecule that has a single amino acid composition against a specific antigen and should not be construed as requiring the antibody to be produced by any particular method. Monoclonal antibodies can be produced by a single clone of B cells or hybridomas, but can also be recombinant, i.e., produced through protein engineering.

[0180] As used herein, the term "antigen" or "target antigen" refers to a molecule or part of a molecule that can be bound by an antibody or antibody-like binding protein. The term further refers to a molecule or part of a molecule that can be used in animals to produce an antibody capable of binding to an epitope of that antigen. A target antigen may have one or more epitopes. For each target antigen recognized by an antibody or by an antibody-like binding protein, the antibody-like binding protein can compete with the intact antibody that recognizes the target antigen.

[0181] As used herein, the term "affinity" is theoretically defined by the balanced association between the intact antibody and the antigen. The affinity of the bispecific antibody of this invention can be assessed or determined by the KD value (dissociation constant) (or other assays), such as bio-layer interferometry (BLI), using a FortebioRed96 instrument.

[0182] As used herein, the term "connector" refers to one or more amino acid residues inserted into the immunoglobulin domain that provide sufficient mobility for both the light and heavy chain domains to fold into an exchangeable dual variable region immunoglobulin.

[0183] Suitable examples of linkers include monoglycine (Gly) or serine (Ser) residues, and the identification and sequence of amino acid residues in the linker can vary depending on the type of secondary structural element to be achieved in the linker. A preferred linker is as follows:

[0184] L1, L2, L3 or L4 are each independently selected from none or Gn (n is selected from 1-10), (GS)n, (G4S)n (n is selected from 1-4), G4SG, GGSGG, SSSSKAPPPSLPSPSRLPGPSDTPILPQ (SEQ ID NO.32), (G)nSSSSKAPPPSLPSPSRLPGPSDTPILPQ(G)m (n is selected from 1-5, m is selected from 1-5).

[0185] Bispecific antibodies (bifunctional antibodies)

[0186] Bispecific antibodies (bsAbs) are non-natural antibodies that simultaneously target two different antigens or proteins, blocking two different signaling pathways and stimulating a specific immune response. Their specificity and dual functionality are playing an increasingly important role in tumor immunotherapy, making them a research hotspot in antibody engineering for cancer treatment worldwide. Studies have shown that bispecific antibodies in tumor immunotherapy primarily mediate the killing of tumors by immune cells; bind to two targets, block two signaling pathways, and exert unique or overlapping functions, effectively preventing drug resistance; possess strong specificity and targeting capabilities, and reduce off-target toxicity; and effectively reduce treatment costs (excerpt from Antibody Circle). Therefore, using bispecific antibody drugs can reduce the chance of tumor cell escape, eliminate tumor cells, and improve efficacy.

[0187] Bispecific antibodies can be prepared using methods such as hybridoma cells, chemical conjugation, and recombinant genes. Among these, recombinant gene technology offers greater flexibility in terms of binding sites and yield. According to incomplete statistics, there are currently more than 60 types of bispecific antibodies. Based on their characteristics and structural differences, bispecific antibody structures mainly fall into two categories: those containing an Fc fragment (IgG-like bispecific antibodies, which have Fc-mediated effector functions) and those without an Fc fragment (non-IgG-like bispecific antibodies, which function through antigen-binding affinity and have advantages such as small molecular weight and low immunogenicity).

[0188] As used herein, the terms “bispecific antibody,” “bifunctional antibody,” “bispecific antibody of the present invention,” and “bifunctional fusion antibody” are used interchangeably and refer to anti-PD-L1 / OX40 bispecific antibodies that simultaneously bind to PD-L1 and OX40.

[0189] The bispecific antibody of the present invention includes:

[0190] First antigen-binding domain D1; and

[0191] Second antigen-binding domain D2;

[0192] Specifically, the first antigen-binding domain D1 specifically binds to the PD-L1 protein;

[0193] The second antigen-binding domain D2 specifically binds to the OX40 protein.

[0194] In another preferred embodiment, the anti-PD-L1 antibody or its antigen-binding fragment is linked to a region of the anti-OX40 antibody selected from the group consisting of: a heavy chain variable region, a heavy chain constant region, a light chain variable region, a light chain constant region, or a combination thereof.

[0195] In another preferred embodiment, the anti-OX40 antibody or its antigen-binding fragment is linked to a region of the anti-PD-L1 antibody selected from the group consisting of: a heavy chain variable region, a heavy chain constant region, a light chain variable region, a light chain constant region, or a combination thereof.

[0196] Preferably, the bispecific antibody of the present invention has the structure shown in Formula I from the N-terminus to the C-terminus:

[0197]

[0198] in,

[0199] Each D1 is independently an anti-PD-L1 antibody or its antigen-binding fragment, and at least one D1 is an anti-PD-L1 antibody or its antigen-binding fragment;

[0200] L1, L2, L3, and L4 are each independently keyless, keyless, or connectors;

[0201] VLa represents the light chain variable region of the anti-OX40 antibody;

[0202] CLa represents the light chain constant region of the anti-OX40 antibody;

[0203] VHa represents the heavy chain variable region of the anti-OX40 antibody;

[0204] CHa represents the heavy chain constant region of the anti-OX40 antibody;

[0205] "~" represents a disulfide bond or a covalent bond;

[0206] "-" represents a peptide bond;

[0207] The bispecific antibody has the activity of simultaneously binding to PD-L1 and OX40.

[0208] In another preferred embodiment, the bispecific antibody has the structure shown in Formula II from the N-terminus to the C-terminus:

[0209]

[0210] in,

[0211] Each D2 is independently either an anti-OX40 antibody or an antigen-binding fragment thereof, and at least one D2 is an anti-OX40 antibody or an antigen-binding fragment thereof;

[0212] L1, L2, L3, and L4 are each independently keyless, keyless, or connectors;

[0213] VLb represents the light chain variable region of the anti-PD-L1 antibody;

[0214] CLb represents the light chain constant region of the anti-PD-L1 antibody;

[0215] VHb represents the heavy chain variable region of the anti-PD-L1 antibody;

[0216] CHb represents the heavy chain constant region of the anti-PD-L1 antibody;

[0217] "~" represents a disulfide bond or a covalent bond;

[0218] "-" represents a peptide bond;

[0219] The bispecific antibody has the activity of simultaneously binding to PD-L1 and OX40.

[0220] In a specific embodiment of the present invention, the monoclonal antibody sequence targeting human PD-L1 is derived from the MT02-C4 antibody in Chinese Patent 2018114326870. The heavy chain variable region sequence of MT02-C4 is shown in SEQ ID NO.1; the light chain variable region sequence of MT02-C4 is shown in SEQ ID NO.2.

[0221] The monoclonal antibody sequence targeting human OX40 is a humanized antibody sequence based on the MT01-L1 antibody in Chinese Patent 201711476160.3 (here, the humanized antibody is named MT01-C1). The heavy chain variable region sequence of the humanized antibody MT01-C1 is shown in SEQ ID NO.3; the light chain variable region sequence of the humanized antibody MT01-C1 is shown in SEQ ID NO.4.

[0222] In a specific embodiment of the present invention, the bispecific antibody has an amino acid sequence selected from the group consisting of: (1) the H chain as shown in SEQ ID NO.5; and the L chain as shown in SEQ ID NO.6;

[0223] (2) The H chain as shown in SEQ ID NO.5; and the L chain as shown in SEQ ID NO.7;

[0224] (3) The H chain as shown in SEQ ID NO.8; and the L chain as shown in SEQ ID NO.9;

[0225] (4) The H chain as shown in SEQ ID NO. 10; and the L chain as shown in SEQ ID NO. 9;

[0226] (5) The H chain as shown in SEQ ID NO. 11; and the L chain as shown in SEQ ID NO. 9;

[0227] (6) The H chain as shown in SEQ ID NO. 12; and the L chain as shown in SEQ ID NO. 13;

[0228] (7) The H chain as shown in SEQ ID NO.18; and the L chain as shown in SEQ ID NO.19;

[0229] (8) The H chain as shown in SEQ ID NO.22; and the L chain as shown in SEQ ID NO.19;

[0230] (9) The H chain as shown in SEQ ID NO.23; and the L chain as shown in SEQ ID NO.19;

[0231] (10) The H chain as shown in SEQ ID NO.30; and the L chain as shown in SEQ ID NO.31;

[0232] (11) The H chain as shown in SEQ ID NO.14; and the L chain as shown in SEQ ID NO.15;

[0233] (12) The H chain as shown in SEQ ID NO.16; and the L chain as shown in SEQ ID NO.17;

[0234] (13) The H chain as shown in SEQ ID NO.20; and the L chain as shown in SEQ ID NO.17;

[0235] (14) The H chain as shown in SEQ ID NO.21; and the L chain as shown in SEQ ID NO.17;

[0236] (15) The H chain as shown in SEQ ID NO.24; and the L chain as shown in SEQ ID NO.17;

[0237] (16) The H chain as shown in SEQ ID NO.25; and the L chain as shown in SEQ ID NO.26;

[0238] (17) The H chain as shown in SEQ ID NO.27; and the L chain as shown in SEQ ID NO.26;

[0239] (18) The H chain as shown in SEQ ID NO. 28; and the L chain as shown in SEQ ID NO. 26; or

[0240] (19) The H chain as shown in SEQ ID NO.29; and the L chain as shown in SEQ ID NO.26.

[0241] The bispecific antibodies of this invention include not only complete antibodies, but also fragments of immunologically active antibodies or fusion proteins formed by antibodies and other sequences. Therefore, this invention also includes fragments, derivatives, and analogs of said antibodies. As used herein, the terms “fragment,” “derivative,” and “analyte” refer to polypeptides that substantially retain the same biological function or activity as the antibodies of this invention. The polypeptide fragments, derivatives, or analogs of this invention may be (i) polypeptides in which one or more conserved or non-conserved amino acid residues (preferably conserved amino acid residues) are substituted, and such substituted amino acid residues may or may not be encoded by the genetic code; or (ii) polypeptides having substituent groups in one or more amino acid residues; or (iii) polypeptides formed by fusing a mature polypeptide with another compound (e.g., a compound that extends the half-life of the polypeptide, such as polyethylene glycol); or (iv) polypeptides formed by fusing an additional amino acid sequence to this polypeptide sequence (e.g., a leader sequence or secretion sequence, or a sequence used to purify this polypeptide, or a proteogenic sequence, or a fusion protein formed with a 6His tag). Based on the teachings herein, these fragments, derivatives, and analogs are within the scope well known to those skilled in the art.

[0242] The bispecific antibody of this invention refers to an antibody comprising two structures of Formula I described above, possessing anti-PD-L1 and anti-OX40 activity. This term also includes variants of antibodies comprising two structures of Formula I described above, having the same function as the bispecific antibody of this invention. These variants include (but are not limited to): deletions, insertions, and / or substitutions of one or more amino acids (typically 1-50, preferably 1-30, more preferably 1-20, most preferably 1-10), and the addition of one or more amino acids (typically up to 20, preferably up to 10, more preferably up to 5) at the C-terminus and / or N-terminus. For example, in the art, substitution with amino acids of similar or comparable performance generally does not alter the function of the protein. Similarly, the addition of one or more amino acids at the C-terminus and / or N-terminus generally does not alter the function of the protein. This term also includes active fragments and active derivatives of the bispecific antibody of this invention.

[0243] The variants of the bispecific antibody include: homologous sequences, conserved variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA that can hybridize with the encoding DNA of the antibody of the present invention under high or low severity conditions, and polypeptides or proteins obtained using antiserum against the bispecific antibody of the present invention.

[0244] In this invention, the bispecific antibody also includes its conserved variants, which refer to polypeptides formed by replacing up to 10, preferably up to 8, more preferably up to 5, and most preferably up to 3 amino acids with amino acids of similar or analogous properties compared to the amino acid sequence of the bispecific antibody. These conserved variant polypeptides are preferably generated by amino acid substitutions according to Table A.

[0245] Table A

[0246]

[0247]

[0248] Nucleic acid encoding and expression vector

[0249] The present invention also provides polynucleotide molecules encoding the aforementioned antibodies or fragments thereof or fusion proteins thereof. The polynucleotides of the present invention may be in DNA or RNA form. DNA form includes cDNA, genomic DNA, or artificially synthesized DNA. DNA may be single-stranded or double-stranded. DNA may be a coding strand or a non-coding strand. Polynucleotides encoding the mature polypeptides of the present invention include: a coding sequence encoding only the mature polypeptide; a coding sequence of the mature polypeptide and various additional coding sequences; a coding sequence of the mature polypeptide (and optional additional coding sequences) and a non-coding sequence.

[0250] The term "polynucleotide encoding a polypeptide" can refer to a polynucleotide that includes the polypeptide, or it can also include additional coding and / or non-coding sequences.

[0251] The nucleic acids (and combinations of nucleic acids) of the present invention can be used to generate the recombinant antibodies of the present invention in a suitable expression system.

[0252] The present invention also relates to polynucleotides that hybridize with the above-described sequences and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that hybridize with the polynucleotides described herein under stringent conditions. In the present invention, “stringent conditions” means: (1) hybridization and elution at lower ionic strength and higher temperatures, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) hybridization with a denaturing agent, such as 50% (v / v) formamide, 0.1% fetal bovine serum / 0.1% Ficoll, 42°C, etc.; or (3) hybridization only occurs when the identity between the two sequences is at least 90%, more preferably at least 95%. Furthermore, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.

[0253] The full-length nucleotide sequence or fragments of the antibody of the present invention can generally be obtained by PCR amplification, recombinant methods, or artificial synthesis. One feasible method is to synthesize the relevant sequence artificially, especially when the fragment length is short. Typically, long fragments can be obtained by first synthesizing multiple small fragments and then ligating them. Furthermore, the coding sequence of the heavy chain and an expression tag (such as 6His) can be fused together to form a fusion protein.

[0254] Once the relevant sequence is obtained, it can be obtained in large quantities using recombination methods. This typically involves cloning it into a vector, transforming it into cells, and then isolating the sequence from the proliferated host cells using conventional methods. The biomolecules (nucleic acids, proteins, etc.) involved in this invention include biomolecules existing in isolated forms.

[0255] Currently, the DNA sequence encoding the protein of this invention (or a fragment thereof, or a derivative thereof) can be obtained entirely through chemical synthesis. This DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art. Furthermore, mutations can be introduced into the protein sequence of this invention through chemical synthesis.

[0256] The present invention also relates to vectors comprising the aforementioned suitable DNA sequences and suitable promoters or control sequences. These vectors can be used to transform suitable host cells to enable them to express proteins.

[0257] The host cell can be a prokaryotic cell, such as a bacterial cell; a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples include: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; insect cells of Drosophila S2 or Sf9; and animal cells of CHO, COS7, and 293 cells.

[0258] Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art. When the host is a prokaryote such as *E. coli*, competent cells capable of uptake DNA can be harvested after the exponential growth phase and treated with CaCl2, the steps of which are well known in the art. Another method is to use MgCl2. If desired, transformation can also be performed using electroporation. When the host is a eukaryote, the following DNA transfection methods can be used: calcium phosphate coprecipitation, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.

[0259] The obtained transformants can be cultured using conventional methods to express the polypeptide encoded by the gene of this invention. Depending on the host cells used, the culture medium can be selected from various conventional media. Culture is carried out under conditions suitable for host cell growth. Once the host cells have grown to an appropriate cell density, the selected promoter is induced using a suitable method (such as temperature adjustment or chemical induction), and the cells are cultured for a further period.

[0260] In the early culture conditions, the expression level of bispecific antibodies can reach 3.9 g / L, with a purity of over 97%, and they can effectively metabolize lactic acid during the culture process.

[0261] The recombinant peptides used in the methods described above can be expressed intracellularly, on the cell membrane, or secreted extracellularly. If desired, the recombinant proteins can be separated and purified using various separation methods based on their physical, chemical, and other properties. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to: conventional refolding treatment, treatment with protein precipitants (salting out), centrifugation, permeation, ultrafiltration, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high-performance liquid chromatography (HPLC), and various other liquid chromatography techniques, as well as combinations of these methods.

[0262] The bispecific antibody of the present invention can be used alone or in combination or conjugated with a detectable marker (for diagnostic purposes), a therapeutic agent, or any combination of the above substances.

[0263] Detectable markers for diagnostic purposes include, but are not limited to: fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (computed tomography) contrast agents, or enzymes capable of producing detectable products.

[0264] Therapeutic agents that can bind to or conjugate with the antibodies of the present invention include, but are not limited to: 1. radionuclides; 2. biotoxicants; 3. cytokines such as IL-2; 4. gold nanoparticles / nanorobars; 5. viral particles; 6. liposomes; 7. magnetic nanoparticles; 8. tumor therapeutic agents (e.g., cisplatin) or any form of antitumor drug, etc.

[0265] Pharmaceutical Composition

[0266] The present invention also provides a composition. Preferably, the composition is a pharmaceutical composition containing the bispecific antibody or its active fragment or fusion protein described above, and a pharmaceutically acceptable carrier. Typically, these substances are formulated in a non-toxic, inert, and pharmaceutically acceptable aqueous carrier medium, wherein the pH is generally about 5-8, preferably about 6-8, although the pH may vary depending on the nature of the formulated substance and the condition to be treated. The formulated pharmaceutical composition can be administered via conventional routes, including (but not limited to): intravenous injection, intravenous infusion, subcutaneous injection, local injection, intramuscular injection, intratumoral injection, intraperitoneal injection (e.g., intraperitoneal), intracranial injection, or intracavitary injection.

[0267] The pharmaceutical compositions of the present invention can be directly used to bind to PD-L1 protein molecules or PD-L1, and therefore can be used to treat tumors. In addition, other therapeutic agents can be used simultaneously.

[0268] The pharmaceutical compositions of the present invention contain a safe and effective amount (e.g., 0.001-99 wt%, preferably 0.01-90 wt%, more preferably 0.1-80 wt%) of the above-described nanobody (or conjugate thereof) of the present invention, and a pharmaceutically acceptable carrier or excipient. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical formulation should be matched to the route of administration. The pharmaceutical compositions of the present invention can be formulated into injectable forms, for example, prepared by conventional methods using physiological saline or an aqueous solution containing glucose and other excipients. Pharmaceutical compositions such as injections and solutions are preferably manufactured under sterile conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 10 micrograms / kg body weight to about 50 milligrams / kg body weight per day. Furthermore, the peptides of the present invention can also be used with other therapeutic agents.

[0269] In this invention, bispecific antibodies can be used alone, and the optimal target response can be obtained by adjusting the dosing regimen. For example, a single dose, multiple doses over a period of time, or the dose can be reduced or increased proportionally according to the urgency of the treatment situation.

[0270] When using a pharmaceutical composition, a safe and effective amount of the immunoconjugate is administered to mammals. This safe and effective amount is typically at least about 10 micrograms per kilogram of body weight, and in most cases does not exceed about 50 milligrams per kilogram of body weight. Preferably, the dose is between about 10 micrograms per kilogram of body weight and about 10 milligrams per kilogram of body weight. Of course, the specific dosage should also take into account factors such as the route of administration and the patient's health condition, which are all within the scope of a skilled physician's expertise.

[0271] Immunoconjugates

[0272] The present invention also provides immunoconjugates based on the antibodies of the present invention, preferably antibody-drug conjugates (ADCs).

[0273] Typically, the antibody-drug conjugate comprises an antibody and an effector molecule, wherein the antibody is conjugated to the effector molecule, preferably chemically conjugated. The effector molecule is preferably a drug with therapeutic activity. Furthermore, the effector molecule may be one or more of a toxic protein, a chemotherapeutic agent, a small molecule drug, or a radionuclide.

[0274] The bispecific antibody of the present invention can be coupled to the effector molecule via a coupling agent. Examples of the coupling agent include any one or more of non-selective coupling agents, carboxyl-based coupling agents, peptide chains, and disulfide-based coupling agents. The non-selective coupling agent refers to a compound that covalently links the effector molecule and the antibody, such as glutaraldehyde. The carboxyl-based coupling agent can be any one or more of maleic aconitine-based coupling agents (e.g., maleic aconitine) and acylhydrazone-based coupling agents (with an acylhydrazone as the coupling site).

[0275] Certain residues on antibodies (such as Cys or Lys) are used to link to a variety of functional groups, including imaging reagents (e.g., chromophores and fluorophores), diagnostic reagents (e.g., MRI contrast agents and radioisotopes), stabilizers (e.g., ethylene glycol polymers), and therapeutic agents. Antibodies can be conjugated to functional agents to form antibody-functional agent conjugates. Functional agents (e.g., drugs, detection reagents, stabilizers) are conjugated (covalently linked) to antibodies. Functional agents can be directly attached to antibodies or indirectly through linkers.

[0276] Antibodies can be conjugated to drugs to form antibody-drug conjugates (ADCs). Typically, an ADC contains a linker between the drug and the antibody. The linker can be degradable or non-degradable. Degradable linkers are typically readily degraded in intracellular environments, such as at the target site, thereby releasing the drug from the antibody. Suitable degradable linkers include, for example, enzyme-degradable linkers, including peptide-containing linkers that can be degraded by intracellular proteases (e.g., lysosomal proteases or endosomal proteases), or sugar linkers, such as glucuronidase-containing linkers. Peptide linkers can include, for example, dipeptides, such as valine-citrulline, phenylalanine-lysine, or valine-alanine. Other suitable degradable linkers include, for example, pH-sensitive linkers (e.g., linkers that hydrolyze at pH less than 5.5, such as hydrazone linkers) and linkers that degrade under reducing conditions (e.g., disulfide linkers). Non-degradable linkers typically release the drug under conditions where the antibody is hydrolyzed by proteases.

[0277] Prior to attachment to the antibody, the linker has a reactive group capable of reacting with certain amino acid residues, and the attachment is achieved through the reactive group. Thiol-specific reactive groups are preferred and include, for example, maleimide compounds, haloamides (e.g., iodinated, brominated, or chlorinated); haloesters (e.g., iodinated, brominated, or chlorinated); halomethyl ketones (e.g., iodinated, brominated, or chlorinated); benzyl halides (e.g., iodinated, brominated, or chlorinated); vinyl sulfones; pyridyl disulfides; mercury derivatives such as 3,6-di-(mercurymethyl)dioxane, with the counter ion being acetate, chloride, or nitrate; and polymethylene dimethyl sulfide thiosulfonate. The linker may include, for example, a maleimide attached to the antibody via a thiosuccinimide.

[0278] The drug can be any cytotoxic, cell growth-inhibiting, or immunosuppressive drug. In one embodiment, the linker connects the antibody and the drug, and the drug has a functional group that can bond with the linker. For example, the drug may have an amino, carboxyl, thiol, hydroxyl, or ketone group that can bond with the linker. In the case where the drug is directly linked to the linker, the drug has a reactive group before being linked to the antibody.

[0279] Useful drug classes include, for example, anti-tubulin drugs, DNA minor groove binding agents, DNA replication inhibitors, alkylating agents, antibiotics, folic acid antagonists, antimetabolites, chemotherapy sensitizers, topoisomerase inhibitors, and vinca alkaloids. Examples of particularly useful cytotoxic drugs include, for example, DNA minor groove binding agents, DNA alkylating agents, and tubulin inhibitors. Typical cytotoxic drugs include, for example, auristatins, camptothecins, duocarmycins, etoposides, maytansines and maytansinoids (e.g., DM1 and DM4), taxanes, benzodiazepines or benzodiazepine-containing drugs (e.g., pyrrolo[1,4]benzodiazepines (PBDs), indolinobenzodiazepines and oxazolidinobenzodiazepines) and vinca alkaloids.

[0280] In this invention, the drug-linker can be used to form an ADC in a simple step. In other embodiments, bifunctional linker compounds can be used to form an ADC in a two- or multi-step process. For example, cysteine ​​residues react with the reactive portion of the linker in a first step, and in a subsequent step, the functional groups on the linker react with the drug to form an ADC.

[0281] Typically, functional groups on the linker are selected to facilitate specific reaction with suitable reactive groups on the drug moiety. As a non-limiting example, azide-based moieties can be used to specifically react with reactive alkynyl groups on the drug moiety. The drug is covalently bound to the linker via a 1,3-dipolar cycloaddition between the azide and alkynyl groups. Other useful functional groups include, for example, ketones and aldehydes (suitable for reaction with hydrazides and alkoxyamines), phosphine (suitable for reaction with azides); isocyanates and isothiocyanates (suitable for reaction with amines and alcohols); and activated esters, such as N-hydroxysuccinimide esters (suitable for reaction with amines and alcohols). These and other linking strategies, such as those described in Bioconjugation Techniques, Second Edition (Elsevier), are well known to those skilled in the art. Those skilled in the art will understand that for selective reaction between the drug moiety and the linker, when a complementary pair of reactive functional groups is selected, each member of that complementary pair can be used for either the linker or the drug.

[0282] The present invention also provides a method for preparing an ADC, which may further include: binding an antibody to a drug-adaptor compound under conditions sufficient to form an antibody-drug conjugate (ADC).

[0283] In some embodiments, the method of the present invention includes binding an antibody to a bifunctional adapter compound under conditions sufficient to form an antibody-adaptor conjugate. In these embodiments, the method of the present invention further includes binding the antibody-adaptor conjugate to a drug moiety under conditions sufficient to covalently link a drug moiety to the antibody via the adapter.

[0284] In some implementations, the antibody-drug conjugate (ADC) has the following molecular formula:

[0285]

[0286] in:

[0287] Ab is an antibody.

[0288] LU stands for connector;

[0289] D is a drug;

[0290] Furthermore, the subscript p is a value selected from 1 to 8.

[0291] The main advantages of this invention include

[0292] (1) The bispecific antibody of the present invention is characterized by its high activity in targeting and blocking PD-L1-PD1 interaction, and can only generate moderate OX40 agonist activity after it binds to PD-L1 on the tumor surface. Therefore, its OX40 agonist activity has a certain tumor microenvironment specificity.

[0293] (2) The bispecific antibody of the present invention does not have the FcR-dependent OX40 agonist activity of the usual OX40 agonist monoclonal antibody. Therefore, even at high blood drug concentrations, it will not produce excessive agonist activity on T cells in the circulating blood system, thus avoiding the side effects caused by excessive activation of the immune system.

[0294] The present invention will be further described below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or as recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.

[0295] Example 1: Design and Expression of Bispecific Antibodies

[0296] 1.1 Bispecific antibody design

[0297] The monoclonal antibody sequence targeting human PD-L1 is derived from the MT02-C4 antibody in Chinese patent 2018114326870. Specific sequence information is as follows:

[0298] The heavy chain variable region sequence of MT02-C4 is SEQ ID NO.1:

[0299] QVQLQESGPGLVKPSETLSLTCTVSGDSITSGYWSWIRQPPGKGLEYMGYISYTGSTYYSPSLIRRMTISRDTSKNQFSLKLSSVTAADTAVYYCAKYENWKEGYFDIWGQGTLVTVSS

[0300] The light chain variable region sequence of MT02-C4 is SEQ ID NO.2:

[0301] DIQMTQSPSSSLSASVGDRVTITCKASQNVGINVAWYQQKPGKAPKALIYSATQRYSGVPSKFSGSGSGTDFTLTISSLQPEDFATYFCQQYYGYPLTFGQGTRLEIK

[0302] The monoclonal antibody sequence targeting human OX40 is a humanized antibody sequence based on the MT01-L1 antibody in Chinese patent 201711476160.3 (here, this humanized antibody is named MT01-C1). Specific sequence information is as follows:

[0303] The heavy chain variable region sequence of the humanized antibody MT01-C1 is SEQ ID NO.3:

[0304] EVQLVQSGAEVKKPGESLKISCKASGYTFTSYVMHWLRQMPGKGLEWMGYINPYNDGTKYNEKFKGQVTISSDKSISTAYLQWSSLKASDTAMYYCANYYGSKFAMDYWGQGTMVTVSS

[0305] The light chain variable region sequence of the humanized antibody MT01-C1 is SEQ ID NO.4:

[0306] DIQMTQSPSSVSASVGDRVTITCRASQDISNYLSWYQQKPGGAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYFCQQGITLPWTFGQGTKVEIK

[0307] Bispecific antibodies can be formed by combining anti-human PD-L1 antibodies or their antigen-binding domains with anti-human OX40 antibodies or their antigen-binding domains in different ways. To avoid mismatches between the heavy and light chains of the antibodies, several symmetrical bispecific antibody forms were selected and tested, specifically as follows: Figure 1 As shown.

[0308] For each bispecific antibody structure, the inventors tried different combinations of antibody subtypes, VH / VL order in scFv, linker sequence, and different mutations. The specific bispecific antibody sequences are shown in Table 1.

[0309] 1.2 Antibody Expression

[0310] The cDNA sequences encoding the antibody heavy or light chain were ligated to the sequences encoding the signal peptide and cloned into the mammalian cell expression vector pcDNA3.4, respectively. HEK293 cells were transfected with Lipofectamine 2000 transfection reagent (Invitrogen) at a 2:1 molar ratio using heavy and light chain expression plasmids and cultured at 37°C and 5% CO2 for 7 days. The culture supernatant was collected, and the antibody was purified from the supernatant using Protein A affinity chromatography. The quality of the purified antibody was analyzed using classic protein analysis methods such as SDS-PAGE electrophoresis and molecular sieve chromatography. The purified antibody was dialyzed against PBS and lyophilized for concentration before being stored at -20°C. Antibody expression is shown in Table 1.

[0311] Table 1. Sequences and types of PD-L1-OX40 bispecific antibodies

[0312]

[0313] *Amino acid positions are numbered using Kabat. YTE: M252Y / S254T / T256E; LALA: L234A / L235A; H44L00: The heavy chain at position 44 and the light chain at position 100 are mutated to cysteine.

[0314] **Antibody purity was measured using SEC. 214nM Detection. NA: Not available

[0315] Example 2: Activity of bispecific antibody targeting PD-L1

[0316] To examine the effects of different bispecific antibodies on PD-L1 targeting activity, the activity of each antibody against the PD-L1 target was evaluated from several aspects, including protein-level binding activity, blocking activity, cell-level binding, and signaling pathway level.

[0317] 2.1 Binding of bispecific antibodies to PD-L1 protein (ELISA)

[0318] Coat 96-well high-affinity plates with 100 μL / well of 1 μg / mL human PD-L1 protein solution and incubate overnight at 4°C with shaking. The next day, wash three times with 300 μL PBST (Tween 20: 0.5‰), then block with 100 μL / well of 5% BSA / PBS for 1 hour with shaking at room temperature. Wash three times with 300 μL PBST. Prepare serial dilutions of antibody samples using PBS. Add 100 μL / well to each well of the 96-well plate and incubate for 1 hour with shaking at room temperature. Wash three times with 300 μL PBST. Prepare secondary antibody goat anti-human IgGHRP solution and add 100 μL / well to each well of the 96-well plate. Incubate for 30 minutes with shaking at room temperature. Wash four times with 300 μL PBST. Add 100 μL / well of TMB and develop for 5-10 minutes. Add 100 μL / well of 0.6N H2SO4 to stop the development and measure OD. 450 nm.

[0319] Representative data on the binding of the antibody to the PD-L1 protein involved in this invention are shown in Table 2.

[0320] 2.2 Blocking activity of bispecific antibodies against the interaction between PD-L1 and PD1 proteins

[0321] The inventors of this application have constructed an experimental system for blocking PD-L1 and PD1 at the cellular level. Specifically, the inventors of this application have constructed a stable cell line of CHO-PD-L1. When the antibody is incubated with the cells, the antibody can block the binding of PD-L1 on the cells to exogenous human PD1 protein.

[0322] CHO-PD-L1 cells were collected, counted, and then the cell suspension was prepared in PBS and evenly spread in 96-well round-bottom plates. 2X antibody dilution buffer was prepared, and an equal volume of the sample dilution buffer was mixed with the cells. The plates were incubated at 4°C on a shaker for 1 hour. A specific concentration of exogenous human PD1 protein dilution buffer was prepared. The cell plate was centrifuged, the supernatant was discarded, and the cells were washed twice with PBS buffer. The PD1 protein dilution buffer was added and mixed, and the plates were incubated at 4°C on a shaker for 30 minutes. The supernatant was discarded after centrifugation, and the cells were washed twice with PBS buffer. The cells were then resuspended in PBS buffer for detection.

[0323] The data on the blocking activity of the antibody of the present invention against the interaction between PD-L1-PD1 proteins are shown in Table 2.

[0324] 2.3 Activation activity of bispecific antibodies on cellular NFAT signaling pathway

[0325] The inventors of this application have constructed a cell experimental system for detecting the enhanced NFAT signaling pathway activity of PD-L1 antibody. Specifically, the inventors constructed stable cell lines CHO-PD-L1-OKT3 and Jurkat-PD1-NFAT-luciferase. When the bispecific antibody was incubated with CHO-PD-L1-OKT3 cells, the antibody blocked the binding of PD-L1 to PD1, thereby enhancing the activation of the NFAT signaling pathway by OKT3. This enhanced signaling pathway activity can be assessed by detecting the expression of the luciferase reporter gene.

[0326] CHO-PD-L1-OKT3 cells were collected, resuspended in culture medium, and seeded into 384-well plates. The plates were incubated overnight. 2X antibody dilution buffer was prepared at an initial concentration of 20 nM, using a 3-fold gradient. The original culture medium in the plates was discarded, and 15 μL / well of the sample dilution buffer was added to each well. The plates were then pre-incubated for 30 min. Jurkat-PD1-NFAT-luciferase cell suspension was collected and added at 15 μL / well. The plates were incubated for 4 hours. Afterward, 96-well plates were equilibrated to room temperature, and 30 μL / well of One-Glo was added to detect bioluminescence readings. The results were used to fit an activation activity curve using Graphpad software, and the EC50 was calculated.

[0327] Representative data for the antibody NFAT reporter assay involved in this invention are shown in Table 2, where EC50 / EC50 MT02-C4 This represents the ratio of the EC50 of the bispecific antibody to the control PD-L1 monoclonal antibody (MT02-C4); TOP / TOP MT02-C4 This represents the ratio of the bispecific antibody to the highest agonistic intensity of MTO2-C4 in this experiment.

[0328] Table 2. Activity of bispecific antibodies targeting PD-L1 protein

[0329]

[0330]

[0331] *NA: Not available

[0332] Compared with the control PD-L1 monoclonal antibody, L26 can efficiently block the interaction between PD-L1 and PD1 proteins; in addition, L26 also retains appropriate NFAT signaling pathway activation activity.

[0333] Example 3: Bispecific antibody targeting OX40 activity

[0334] To examine the effects of different bispecific antibodies on OX40 targeting activity, we evaluated the activity of each antibody against the OX40 target at both the protein level and the signaling pathway level.

[0335] 3.1 Binding of bispecific antibodies to OX40 protein

[0336] The method used in this experiment is the same as that described in section 2.1, except that the protein used to coat the 96-well plate was replaced with OX40 protein.

[0337] Representative data on the binding of the antibody to the OX40 protein involved in this invention are shown in Table 3.

[0338] Furthermore, the OX40 signaling pathway activating activity of the bispecific antibody molecule in this invention was examined. The bispecific antibody molecule may activate OX40 in two modes:

[0339] 1) After antibody Fc binds to FcR on APC cells to form multimers, it activates the OX40 signaling pathway on T cells;

[0340] 2) Antibodies and PD-L1 + After cell-cell binding and multimerization, the OX40 signaling pathway on T cells is activated. This pathway allows the OX40 agonistic activity of the bispecific antibody molecules to be restricted to PD-L1. + Near cells, such as tumor cells, the drug can more precisely activate tumor-infiltrating T cells, thereby increasing the safety window for drug action.

[0341] 3.2 FcR-dependent OX40 signaling pathway agonist activity

[0342] The inventors of this application have constructed a cell experimental system for detecting the function of OX40 activating antibodies. Specifically, the inventors of this application have constructed a stable HEK293T-OX40-NFκB-luciferase reporter cell line. When the OX40 activating antibody is mixed with this stable cell line and HEK293 cells overexpressing FcR, the OX40 antibody can activate the expression of the NFκB-luciferase reporter gene.

[0343] Prepare an OX40 antibody gradient using PBS to achieve a final concentration of 2× working solution, and operate on ice. Collect HEK293T-OX40-NFκB cells and FcR-overexpressing HEK293 cells, centrifuge, and resuspend in culture medium. Add OX40 Ab and an appropriate amount of cell suspension to 384-well plates, incubate for 5 hours, add One-Glo (Promega) assay reagent, mix well, and detect fluorescence signal using Pherastar. The detection results were used to fit an activation activity curve using Graphpad software, and EC50 was calculated.

[0344] Representative data on the FcR-dependent OX40 agonist activity of the antibody involved in this invention are shown in Table 3.

[0345] 3.3 PD-L1-dependent OX40 signaling pathway agonist activity

[0346] The assay method for PD-L1-dependent OX40 signaling pathway activating activity was the same as described in 3.2, except that HEK293 cells overexpressing FcR were replaced with CHO-K1 cells overexpressing PD-L1.

[0347] Representative data on the PD-L1-dependent OX40 agonist activity of the antibody involved in this invention are shown in Table 3.

[0348] Table 3. Activity of bispecific antibodies targeting OX40 protein

[0349]

[0350]

[0351] NA: not available; ND: not detected. If the activation factor is less than 15% of MT01-C1, it is marked as ND.

[0352] *: The calculation formula is (activation fold of reporter gene of bispecific antibody - 1) / (activation fold of MT01-C1 - 1).

[0353] **The calculation formula is (reporter gene activation fold of the bispecific antibody - 1) / (activation fold of UM09-CTRL - 1). The control antibody UM09-CTRL is the PD-L1-OX40 bispecific antibody in patent WO2020151761 (SEQ ID NO.1 (heavy chain) and SEQ ID NO.7 (light chain) in WO2020151761).

[0354] The above results indicate that among many bispecific antibody molecules, the L26 molecule mainly activates the OX40 signaling pathway on T cells through the PD-L1-dependent OX40 signaling pathway, while its FcR-dependent OX40 signaling pathway activating activity is almost non-existent. Therefore, the L26 molecule was selected for subsequent experiments.

[0355] Example 4 Affinity Detection

[0356] The affinity of L26 molecules for human PD-L1 and human OX40 was detected using SPR (Surface Plasmon Resonance) technology. In simple terms, antibody capture was achieved by incubating a 4 μg / mL antibody solution with a protein A sensor chip (GE, Cat#29127556) for 30 s. During the antigen binding phase, human PD-L1 and human OX40 proteins were used as mobile phases to bind to the antibodies captured on the sensor chip for 120 s each. In the dissociation phase, elution was performed continuously with HBS-EP buffer for 360 s. The binding of antigens to antibodies on the sensor chip was quantitatively detected using a Biacore 8K.

[0357] The results are as follows Figure 2 As shown in Table 4 below.

[0358] Table 4. Affinity test of bispecific antibody molecule L26

[0359] receptor ka(1 / Ms) kd(1 / s) KD(M) PD-L1 7.86E+05 6.18E-04 7.86E-10 OX40 5.92E+03 2.54E-04 4.30E-08

[0360] The above affinity test results show that bispecific antibody molecules, represented by L26 molecules, have a high affinity for human PD-L1, while their affinity for the human OX40 target is significantly weakened.

[0361] Example 5: Mouse Tumor Drug Efficacy Model

[0362] A mouse colorectal cancer cell line MC38-huPD-L1 expressing human PD-L1 protein was constructed, and its mouse PD-L1 gene was knocked out. Cells were cultured until they reached a good state and then... 6 Cell / mouse quantity: MC38-huPD-L1 cells were subcutaneously in female C57BL6-huOX40 mice. Tumors were allowed to grow to approximately 70 mm. 3 Subsequently, the antibody solution prepared in physiological saline was administered intravenously. Five mice in each group were given the drug twice a week for a total of four times.

[0363] The results are as follows Figure 3 As shown, all three doses of the bispecific antibody exhibited clear tumor-inhibiting effects, and the t-test showed highly significant differences compared to the control group (t<0.001).

[0364] The tumor inhibition rate (TGI) of each treatment group at the experimental endpoint (day 10) is shown in Table 5 below:

[0365] Table 5. TGI at different doses of bispecific antibody as the experimental endpoint

[0366] Group TGI@Day10 UM09-L26 L (0.67mg / kg) 58.48 UM09-L26M (2mg / kg) 69.13 UM09-L26H (6mg / kg) 84.47

[0367] Example 6: PKPD of L26 in a cynomolgus monkey model

[0368] 6.1 Binding of L26 to PD-L1 and OX40 proteins in cynomolgus monkeys

[0369] The binding activity of the double antibody sample to cynomolgus monkey OX40 and PD-L1 was detected by ELISA, as described in Examples 2.1 and 3.1. The results showed that the L26 molecule bound to both cynomolgus monkey OX40 and PD-L1, and the binding strength was similar to that of human proteins. The results are as follows... Figure 4 As shown (EC50: unit ng / mL).

[0370] 6.2 PK Properties of L26 on the Crab-eating Macaque Model

[0371] The antibody solution was intravenously injected into cynomolgus monkeys (n=2) at a dose of 20 mg / kg, BIW x 2. Blood samples were collected at 0, 0.25, 1, 2, 4, 8, 24, 48, 72, 96, 168, 168.5, 170, 176, 192, 216, 240, 264, and 336 hours before and after administration. Blood drug concentration was detected by ELISA (OX40-coated 96-well plates), and a drug-time curve was plotted. The results are as follows. Figure 5 As shown.

[0372] 6.3 PD properties and hematologic toxicity of L26 in a cynomolgus monkey model

[0373] Blood samples were collected 1 day before administration and on days 3, 7, 10, and 14 after administration to detect hematological and biochemical parameters and CD4 / CD8 T cell proliferation. No significant changes were found in hematological and biochemical parameters compared to the pre-administration baseline. Ki67 levels in CD4 and CD8 cells were measured, and it was found that Ki67 levels in both CD4 and CD8 cells reached their peak on day 10 after administration. Figure 6 This demonstrates that L26 has significant T cell proliferation-promoting activity.

[0374] Example 7: The stability of L26 in molecules

[0375] 7.1 Thermal melting curve

[0376] Tycho assesses protein quality by detecting structural integrity. During system heating, the intrinsic fluorescence of tryptophan and tyrosine residues within the protein is recorded at wavelengths of 350 nm and 330 nm. Changes in these fluorescence signals indicate transitions in the protein's folded state. The temperature at which this transition occurs is called the inflection point temperature (Ti). During heating, the fluorescence signal is recorded, and the ratio of 350 nm to 330 nm is used to calculate the Ti value. The initial value of this ratio and the signal change (Δratio) throughout the experiment are also recorded. A small sample of the test is taken, ensuring a protein concentration of approximately 1 mg / ml, with a volume of about 100 μl, and the operation is performed according to the instrument requirements. At the end of the experiment, the raw data and analysis results are exported, and the results are summarized and analyzed.

[0377] like Figure 7 The curve shown is the derivative of the ratio of 350 nm to 330 nm, illustrating the rate of change of the Δratio of the L26 protein. The temperature corresponding to the peak of the curve is the Ti value. The results show that the Ti value of L26 is 77.6℃, indicating that it is a relatively stable protein.

[0378] 7.2 Accelerated Stability Test

[0379] The L26 protein was stored at 37°C for 28 days, with samples taken weekly and frozen. After sampling at week 4, the binding activity of the penicillin antibody samples to human OX40 and human PD-L1 was measured using ELISA, as described in Examples 2.1 and 3.1. Results are as follows: Figure 8 As shown, the activity (EC50, nM) of the sample placed for accelerated stability remained essentially unchanged, indicating that L26 has good thermal stability.

[0380] The bispecific antibody sequences of this invention are shown in the table below:

[0381] Table 6. Sequences of different bispecific antibodies

[0382]

[0383]

[0384]

[0385]

[0386]

[0387]

[0388]

[0389] All documents mentioned in this invention are incorporated herein by reference as if each document were individually incorporated by reference. Furthermore, it should be understood that after reading the foregoing teachings of this invention, those skilled in the art can make various alterations or modifications to this invention, and these equivalent forms also fall within the scope defined by the appended claims.

Claims

1. A bispecific antibody, characterized in that, The bispecific antibody includes: First antigen-binding domain D1; and Second antigen-binding domain D2; Specifically, the first antigen-binding domain D1 specifically binds to the PD-L1 protein; The second antigen-binding domain D2 specifically binds to the OX40 protein; The bispecific antibody has a heavy chain (H chain) and a light chain (L chain), and the amino acid sequence of the H chain of the bispecific antibody is shown in SEQ ID NO. 30, and the amino acid sequence of the L chain is shown in SEQ ID NO. 31; the bispecific antibody is a homodimer.

2. An isolated polynucleotide, characterized in that, The polynucleotide encodes the bispecific antibody of claim 1.

3. A carrier, characterized in that, The carrier contains the polynucleotide as described in claim 2.

4. A genetically engineered host cell, characterized in that, The host cell contains the vector of claim 3 or the genome is integrated with the polynucleotide of claim 2.

5. A pharmaceutical composition, characterized in that, The pharmaceutical composition contains: (I) The bispecific antibody as described in claim 1; and (II) Pharmaceutically acceptable carriers.

6. An immunoconjugate, characterized in that, The immunoconjugate includes: (a) The bispecific antibody as described in claim 1; and (b) Coupling part: Detectable marker.

7. The use of the bispecific antibody as described in claim 1 or the immunoconjugate as described in claim 6, characterized in that, For use in the preparation of (a) a detection reagent or kit for detecting PD-L1 and / or OX40; and / or (b) a pharmaceutical composition for treating tumors, said tumor being colorectal cancer.

Citation Information

Patent Citations

  • Isolated antibody or antigen-binding fragment thereof and application of isolated antibody or antigen-binding fragment thereof in tumor therapy

    CN108218990A

  • Bispecific antibody binding to PD-l1 and ox40

    WO2020151761A1

  • Anti-human PD-L1 antibody and antigen-binding fragment thereof, and preparation methods and applications of anti-human PD-L1 antibody or antigen-binding fragment thereof

    CN111234017A

  • Anti-PD-L1 and OX40 bispecific antibody and application thereof

    CN114478789A

  • Fusion protein and its application in preparing medicine for treating tumor and / or viral infection

    WO2020048454A1